Home Triferic: The Kill Shot For AMAG Pharmaceuticals' Feraheme
 

Keywords :   


Triferic: The Kill Shot For AMAG Pharmaceuticals' Feraheme

2015-01-28 14:36:45| Biotech - Topix.net

Cruise-1/-2 Phase III trials met all primary and secondary endpoints with safety equivalent to placebo resulting in a highly differentiated and disruptive new entry into CKD market. AMAG Pharmaceuticals has issued puzzling guidance for Feraheme in 2015: Sales are projected to grow from ~$86 Million in 2014 to a range of approximately $86-102 MM in 2015 .

Tags: shot kill pharmaceuticals amag

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
01.11Boeing makes 38% pay rise offer in bid to end strike
01.11The house paints that promise much more than colour
01.11Eastern North Pacific Tropical Weather Outlook
01.11Atlantic Tropical Weather Outlook
01.11Technology adoption: What's on the ag tech horizon for 2025
01.11Technology adoption: What's on the ag tech horizon for 2025
01.11How Japan's youngest CEO transformed Hello Kitty
31.10Unicharm to Expand in Africa
More »